Insulet Co. (NASDAQ:PODD) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its position in Insulet Co. (NASDAQ:PODD – Get Rating) by 2.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,382 shares of the medical instruments supplier’s stock after acquiring an additional 126 shares during the period. Daiwa Securities Group Inc.’s holdings in Insulet were worth $1,235,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Congress Asset Management Co. MA lifted its stake in shares of Insulet by 7.4% in the 2nd quarter. Congress Asset Management Co. MA now owns 7,865 shares of the medical instruments supplier’s stock worth $1,714,000 after acquiring an additional 542 shares during the period. Toronto Dominion Bank lifted its stake in shares of Insulet by 7.3% in the 2nd quarter. Toronto Dominion Bank now owns 15,104 shares of the medical instruments supplier’s stock worth $3,291,000 after acquiring an additional 1,028 shares during the period. Allworth Financial LP lifted its stake in shares of Insulet by 3,362.5% in the second quarter. Allworth Financial LP now owns 277 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 269 shares during the period. Private Advisor Group LLC lifted its stake in shares of Insulet by 4.1% in the second quarter. Private Advisor Group LLC now owns 1,817 shares of the medical instruments supplier’s stock valued at $396,000 after purchasing an additional 71 shares during the period. Finally, Baird Financial Group Inc. lifted its stake in shares of Insulet by 1.7% in the second quarter. Baird Financial Group Inc. now owns 294,253 shares of the medical instruments supplier’s stock valued at $64,129,000 after purchasing an additional 4,838 shares during the period.

Insider Transactions at Insulet

In other news, SVP Dan Manea sold 200 shares of Insulet stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $294.62, for a total transaction of $58,924.00. Following the completion of the sale, the senior vice president now directly owns 3,158 shares in the company, valued at $930,409.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Shacey Petrovic sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $281.88, for a total value of $4,228,200.00. Following the completion of the sale, the director now directly owns 14,789 shares in the company, valued at $4,168,723.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Dan Manea sold 200 shares of the business’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $294.62, for a total transaction of $58,924.00. Following the completion of the sale, the senior vice president now owns 3,158 shares of the company’s stock, valued at $930,409.96. The disclosure for this sale can be found here. Insiders sold a total of 28,858 shares of company stock worth $8,507,309 over the last ninety days. 0.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on PODD shares. Robert W. Baird raised their price objective on shares of Insulet from $315.00 to $340.00 in a research note on Monday, December 12th. Piper Sandler upgraded shares of Insulet from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $235.00 to $340.00 in a research note on Friday, November 4th. BTIG Research raised their price objective on shares of Insulet from $285.00 to $320.00 in a research note on Friday, November 4th. Jefferies Financial Group started coverage on shares of Insulet in a research note on Wednesday, October 12th. They issued a “hold” rating and a $260.00 price objective for the company. Finally, Barclays raised their price objective on shares of Insulet from $238.00 to $245.00 in a research note on Wednesday, January 4th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $309.23.

Insulet Stock Performance

NASDAQ:PODD opened at $294.31 on Monday. The company has a current ratio of 3.98, a quick ratio of 3.00 and a debt-to-equity ratio of 3.22. The firm has a 50-day moving average price of $297.18 and a two-hundred day moving average price of $267.51. Insulet Co. has a twelve month low of $181.00 and a twelve month high of $320.00. The company has a market capitalization of $20.44 billion, a P/E ratio of 1,226.29 and a beta of 0.79.

Insulet (NASDAQ:PODD – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The medical instruments supplier reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.28. The business had revenue of $340.80 million during the quarter, compared to the consensus estimate of $311.84 million. Insulet had a net margin of 1.35% and a return on equity of 18.19%. As a group, research analysts expect that Insulet Co. will post 0.87 earnings per share for the current fiscal year.

Insulet Company Profile

(Get Rating)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.